Bimekizumab in Plaque Psoriasis

Exclusion Criteria

• •Have predominantly pustular, erythrodermic, and/or guttate forms of psoriasis.
• •Have drug induced psoriasis
• •History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection as defined by a positive tuberculin purified protein derivative (PPD) or QuantiFERON TB-Gold test (QFT) at Screening. Participant with a positive or indeterminate PPD or QFT test must be assessed for evidence of active TB versus latent TB within 12 weeks prior to Baseline, including signs and symptoms and chest x-ray. If presence of latent tuberculosis is established, then treatment must have been initiated at least for 4 weeks prior to Baseline and completed. Participant with evidence of active TB may not be enrolled.
• •Participants with a history of HIV, or history of hepatitis C or B infections.
• •Use of any of the following therapies within 4 weeks prior to Baseline (Visit 2): systemic non-biologic psoriasis therapies, including, but not limited to: psoralens (topical or oral) and ultraviolet A (PUVA) therapy, cyclosporine, methotrexate, azathioprine, corticosteroids, apremilast, any JAK or TYK2 Inhibitors, oral retinoids, mycophenolate mofetil, sirolimus, 1, 25 dihydroxyvitamin D analogs, and other forms of phototherapy (including UVB or self-treatment with tanning beds or therapeutic sunbathing).
• •Use of topical corticosteroids, topical calcineurin inhibitors, or other topical preparations with immunomodulatory properties within 2 weeks prior to Baseline (Visit 2).
• •Use of any investigational drug or any systemic drug for psoriasis within 4 weeks prior to Baseline (Visit 2).
• •Serious concomitant illness that could require the use of systemic corticosteroids or otherwise interfere with the participant's participation in the trial.
• •Myocardial infarction or stroke within the 6 months prior to Baseline (Visit 2).
• •Clinically important deviation as judged by the investigator (such WBC\< 3) from normal limits in physical examination, vital sign measurements, clinical laboratory tests results, and not associated with a chronic, well-controlled medical condition.
• •Administration of any live vaccines 3 months prior to Baseline (Visit 2) and during the study.
• •Have a current or history of lymphoproliferative disease within 5 years prior to Baseline (Visit 2); or have current or history of any malignant disease within 5 years prior to Baseline (Visit 2).
• •History of suicide attempt, or are clinically judged by investigator to be at risk of suicide.
• •History of IBD.
• •Acute liver failure/cirrhosis.
• •Had a serious infection, been hospitalized, or received IV antibiotics for an infection, within 12 weeks prior to Baseline (Visit 2).
• •Known immunodeficiency, or history of infection typical of an immunocompromised host.